| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Maciejek Z et al. | Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report. | Neurol. Neurochir. Pol. | pmid:23650003 | |
| Yamasaki T et al. | Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts. | Cell Transplant | pmid:9710310 | |
| Krieger S | Multiple sclerosis therapeutic pipeline: opportunities and challenges. | Mt. Sinai J. Med. | pmid:21425264 | |
| Derwenskus J | Current disease-modifying treatment of multiple sclerosis. | Mt. Sinai J. Med. | pmid:21425262 | |
| Huizinga R and Voyer T | New paradigms in immunosuppression. | CANNT J | pmid:14596200 | |
| Li XK et al. | Induction of lymphocyte apoptosis by a novel immunosuppressant FTY720: relation with Fas, Bcl-2 and Bax expression. | Transplant. Proc. | pmid:9123299 | |
| Li XK et al. | FTY720, a novel immunosuppressive agent, enhances upregulation of the cell adhesion molecular ICAM-1 in TNF-alpha treated human umbilical vein endothelial cells. | Transplant. Proc. | pmid:9123298 | |
| Hussar DA and Zimmerman DE | New drugs: dabigatran etexilate mesylate, fingolimod hydrochloride, and ulipristal acetate. | J Am Pharm Assoc (2003) | pmid:21247838 | |
| Pruvost R and Le Stunff H | [Sphingosine kinase-1: role in non alcoholic fatty liver disease]. | Med Sci (Paris) | pmid:27615179 | |
| Zhang Z et al. | FTY720 attenuates accumulation of EMAP-II+ and MHC-II+ monocytes in early lesions of rat traumatic brain injury. | J. Cell. Mol. Med. | pmid:17488479 | |
| Ubai T et al. | FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. | Anticancer Res. | pmid:17352219 | |
| Katsel P et al. | Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? | Neurochem. Res. | pmid:17342407 | |
| Harrison K | Fingolimod for multiple sclerosis: a review for the specialist nurse. | Br J Nurs | pmid:24933548 | |
| Yopp AC et al. | Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. | Clin Transplant | pmid:17100731 | |
| Francois M et al. | Dealing with excess of zeros in the statistical analysis of magnetic resonance imaging lesion count in multiple sclerosis. | Pharm Stat | pmid:22888087 | |
| Fujino M et al. | T-cell apoptosis triggered by FTY720 via mitochondrial pathway. | Transplant. Proc. | pmid:11750325 | |
| Kahan BD | FTY720: a new dimension in transplantation. | Transplant. Proc. | pmid:11750324 | |
| Brinkmann V et al. | FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. | Transplant. Proc. | pmid:11750323 | |
| Kelly-Laubscher RF et al. | Cardiac preconditioning with sphingosine-1-phosphate requires activation of signal transducer and activator of transcription-3. | Cardiovasc J Afr | pmid:25000441 | |
| Chen S et al. | FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines. | Transplant. Proc. | pmid:11750317 | |
| Huang K et al. | Oral FTY720 administration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice. | Int J Immunopathol Pharmacol | pmid:22697071 | |
| Chun J and Hartung HP | Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. | Clin Neuropharmacol | pmid:20061941 | |
| Troncoso P et al. | FTY 720 prevents ischemic reperfusion damage in rat kidneys. | Transplant. Proc. | pmid:11267102 | |
| Fu F et al. | FTY720, a novel immunosuppressive agent with insulinotropic activity, prolongs graft survival in a mouse islet transplantation model. | Transplant. Proc. | pmid:11267010 | |
| Chueh SC et al. | FTY720 prevents chronic rejection of rat heterotopic cardiac allografts. | Transplant. Proc. | pmid:11266948 | |
| Law SL et al. | Gene transfer mediated by sphingosine/ dioleoylphosphatidylethanolamine liposomes in the presence of poloxamer 188. | Drug Deliv | pmid:16401595 | |
| Brinkmann V et al. | FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. | Transplant. Proc. | pmid:11266942 | |
| Tabasinezhad M et al. | Sphingosin 1-phosphate contributes in tumor progression. | J Cancer Res Ther | pmid:24518696 | |
| pmid: | ||||
| Tedesco-Silva H et al. | FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. | Clin Transplant | pmid:19719728 | |
| Sordillo PP et al. | Review: The Prolonged QT Interval: Role of Pro-inflammatory Cytokines, Reactive Oxygen Species and the Ceramide and Sphingosine-1 Phosphate Pathways. | In Vivo | pmid:26546519 | |
| Sauro S et al. | Di-Calcium Phosphate and Phytosphingosine as an Innovative Acid-Resistant Treatment to Occlude Dentine Tubules. | Caries Res. | pmid:27179116 | |
| Pin D et al. | An emulsion restores the skin barrier by decreasing the skin pH and inflammation in a canine experimental model. | J. Comp. Pathol. | pmid:24975893 | |
| Suleiman M et al. | FTY720 prevents renal T-cell infiltration after ischemia/reperfusion injury. | Transplant. Proc. | pmid:15808648 | |
| Yan S et al. | Control of intestinal allograft rejection by FTY720 and costimulation blockade. | Transplant. Proc. | pmid:15808565 | |
| Galvão VR et al. | Prolonged administration of FTY720 does not cause renal toxicity in mice. | Transplant. Proc. | pmid:15808564 | |
| Schmid G et al. | FTY720 inhibits tumor growth and angiogenesis. | Transplant. Proc. | pmid:15808563 | |
| Kataoka H et al. | Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: II. Effect of FTY720 and FTY720-phosphate on host-versus-graft and graft-versus-host reaction in mice. | Transplant. Proc. | pmid:15808562 | |
| Duan RD | Anticancer compounds and sphingolipid metabolism in the colon. | In Vivo | pmid:15796189 | |
| Lu W et al. | Improved Proliferation and Differentiation of Bone Marrow Mesenchymal Stem Cells Into Vascular Endothelial Cells With Sphingosine 1-Phosphate. | Transplant. Proc. | pmid:26293094 | |
| Yanagawa Y et al. | FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts. | Transplant. Proc. | pmid:10083548 | |
| Suzuki T et al. | Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model. | Transplant. Proc. | pmid:10083540 | |
| Kunikata S et al. | Immunosuppressive action of FTY720 for renal allograft a rat model. | Transplant. Proc. | pmid:10083517 | |
| DeAngelis T and Lublin F | Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. | Mt. Sinai J. Med. | pmid:18500719 | |
| DUBOS RJ | The effect of sphingomyelin on the growth of tubercle bacilli. | 1948 | J. Exp. Med. | pmid:18871879 |
| FISHER N et al. | Action of sphingosine and its derivatives on tuberculin sensitivity in guineapigs. | 1951 | Lancet | pmid:14874428 |
| CARTER HE et al. | Biochemistry of the sphingolipides. VI. The o-methyl ethers of sphingosine. | 1951 | J. Biol. Chem. | pmid:14917665 |
| KERR WR and ROBERTSON M | Effect of ACTH, cortisone, sphingomyelin, sphingosine and phenergan (antihistamine) in inhibiting the skin reaction in cattle sensitized to Trichomonas foetus antigen. | 1952 | J Hyg (Lond) | pmid:12990794 |
| ZABIN I and MEAD JF | The biosynthesis of sphingosine. I. The utilization of carboxyl-labeled acetate. | 1953 | J. Biol. Chem. | pmid:13117905 |
| SADHU DP | Influence of lactose on the transglycosidation of sphingosine base in the rat brain. | 1953 | Am. J. Physiol. | pmid:13114397 |
sphingosine
sphingosine is a lipid of Sphingolipids (SP) class.
Cross Reference
